The Xoft System is FDAĬleared and CE marked for use anywhere in the body, including treatment of non-melanoma skin cancer, early-stage breast cancer and gynecological cancers. Is a painless, non-invasive technology that delivers high dose rate, low energy radiation, which targets cancer while minimizing exposure to surrounding healthy tissue. iCAD offers a comprehensive range of upgradeable computer aided detection (CAD) and workflow solutions to support rapid and accurate detection of breast, prostate and colorectal cancers. ICAD delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and treat cancers earlier and faster Reimbursement from current levels could have a material impact on the Companys revenues. At this point, there is insufficient clarification of the reimbursement matter to assess the potential impact that this matter could have on the Companys guidance for 2015. The Company is proactively addressing the situation in itsĭialogue with Noridian and CMS.
Seek clarification of the Medicare Coverage Articles posted to Noridians web sites. The Company, industry partners and physician providers have reached out to the Centers for Medicare and Medicaid Services (∼MS) and Noridian to
(Nasdaq: ICAD)Īnnounced today that Noridian, the Medicare Administrative Contractor in Jurisdictions EĪnd F, which consists of 13 states primarily on the West Coast, has made recent web postings related to Coding for High Dose Rate Brachytherapy for Non-Melanoma Skin Cancers which instruct physicians to report CPT code (17999) rather than theĮstablished CPT code (0182T) for electronic brachytherapy for non-melanoma skin cancers. ANNOUNCES INFORMATION RELATED TO REIMBURSEMENT LEVELS
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned Press Release of iCAD, Inc., dated May 6, 2015.
Release will not be incorporated by reference into any registration statement filed by the Company under the Securities Act of 1933, as amended, except as set forth by specific reference in such filing. Accordingly, the information in the press The information in the press release is being furnished, not filed, pursuant to Item 7.01.
A copy of the Companys press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Issued a press release announcing information related to reimbursement levels. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) (Former Name or Former Address, if Changed Since Last Report)Ĭheck the appropriate box below if the Form 8-Kįiling is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( (Registrants Telephone Number, Including Area Code) Of Registrant as Specified in Its Charter) ICAD INC (Form: 8-K, Received: 08:15:41)ĭate of report (Date of earliest event reported) May 6, 2015